In a recent study, a combination of MEK and HDAC inhibitors was shown to attenuate RAS-mutated lung cancer progression through increasing cell apoptosis and cell-cycle arrest (Yamada et al., 2018). The gene discussed is HDAC9; the disease is lung cancer.